These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 14522890

  • 1. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 3. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R, Gandhi V, Plunkett W.
    Cancer Res; 2006 Nov 15; 66(22):10959-66. PubMed ID: 17108134
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 5. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 01; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 6. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 7. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 9. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.
    Cancer Res; 2006 Feb 15; 66(4):2305-13. PubMed ID: 16489035
    [Abstract] [Full Text] [Related]

  • 10. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J, Xue L, Hao H, Han Y, Yang J, Luo J.
    Oncol Rep; 2012 Feb 15; 27(2):461-6. PubMed ID: 21993902
    [Abstract] [Full Text] [Related]

  • 11. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.
    Cancer Res; 2005 Apr 15; 65(8):3264-72. PubMed ID: 15833859
    [Abstract] [Full Text] [Related]

  • 12. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 13. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, Ghosh M, Biswas N, Chaudhuri U, Bandyopadhyay S.
    Apoptosis; 2009 Mar 12; 14(3):298-308. PubMed ID: 19153832
    [Abstract] [Full Text] [Related]

  • 14. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 15. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 16. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 17. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
    Dan S, Naito M, Tsuruo T.
    Cell Death Differ; 1998 Aug 01; 5(8):710-5. PubMed ID: 10200527
    [Abstract] [Full Text] [Related]

  • 18. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K, Obermeier A, Mitina O, Simon N, Warmuth M, Krause G, Hallek M.
    Ann Hematol; 2008 Mar 01; 87(3):183-93. PubMed ID: 17960378
    [Abstract] [Full Text] [Related]

  • 19. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 01; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 20. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr 01; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.